6-methyl-chroman-4-one O-methyl-oxime | 890839-03-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6-methyl-chroman-4-one O-methyl-oxime
• 英文别名: (4E)-N-Methoxy-6-methyl-3,4-dihydro-2H-1-benzopyran-4-imine；N-methoxy-6-methyl-2,3-dihydrochromen-4-imine
• CAS: 890839-03-9
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: PQXMCJHBSNVRDL-UHFFFAOYSA-N

物化性质

• 沸点：
  300.4±52.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  30.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-methyl-chroman-4-one O-methyl-oxime 在 镍 氢气 、 乙醚 、 水 、 碳酸氢钠 、 magnesium sulfate 作用下， 以 氨 、 甲醇 为溶剂， 反应 4.0h， 生成 6-甲基苯并二氢吡喃-4-胺
  参考文献：
  名称：

  ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

  摘要：

  本申请涉及的是化合物，其为TRPV1拮抗剂，具有式（I），其中变量Ar1、L1、R1、R2、R3、R4、R5、Y1、Y2和Y3如说明书所定义，对于治疗由vanilloid受体活性引起或加剧的疾病有用。

  公开号：

  US20130165479A1
• 作为产物：
  描述：

  6-甲基-4-苯并二氢呋喃-4-酮 、 甲氧基胺盐酸盐 在 吡啶 、 水 、 乙醚 、 sodium hydroxide 、 盐酸 、 magnesium sulfate 作用下， 以 吡啶 为溶剂， 反应 16.0h， 生成 6-methyl-chroman-4-one O-methyl-oxime
  参考文献：
  名称：

  ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

  摘要：

  本申请涉及的是化合物，其为TRPV1拮抗剂，具有式（I），其中变量Ar1、L1、R1、R2、R3、R4、R5、Y1、Y2和Y3如说明书所定义，对于治疗由vanilloid受体活性引起或加剧的疾病有用。

  公开号：

  US20130165479A1

文献信息

• Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
  申请人：Gomtsyan Arthur

  公开号：US20060128689A1

  公开（公告）日：2006-06-15

  Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A 1 , A 2 , A 3 , A 4 , R 7 , R 8 , R 9 , X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

  对VR1受体拮抗剂，其化学式为(I)或其药用可接受的盐、前药或前药的盐，其中A1、A2、A3、A4、R7、R8、R9、X、Y、Z、L、n和m的定义如本文所述，并且在通过抑制VR1受体预防或改善的疾病中具有用处。
• CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF
  申请人：Gomtsyan Arthur

  公开号：US20110152250A1

  公开（公告）日：2011-06-23

  Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A 1 , A 2 , A 3 , A 4 , R 7 , R 8 , R 9 , X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

  具有以下式子（I）或其药学上可接受的盐、前药或前药的盐的拮抗VR1受体的化合物，在其中A1、A2、A3、A4、R7、R8、R9、X、Y、Z、L、n和m如本文所定义，并且在抑制VR1受体有益于预防或改善疾病。
• Antagonists of the TRPV1 receptor and uses thereof
  申请人：Abbott Laboratories

  公开号：US08030504B2

  公开（公告）日：2011-10-04

  The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

  本申请涉及化合物，其为TRPV1拮抗剂，具有公式(I)，其中变量Ar1、L1、R1、R2、R3、R4、R5、Y1、Y2和Y3如描述中所定义，其可用于治疗由vanilloid受体活性引起或加重的疾病。
• Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
  申请人：Gomtsyan Arthur

  公开号：US08440691B2

  公开（公告）日：2013-05-14

  Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

  化合物是VR1受体的拮抗剂，具有公式(I)或其药学上可接受的盐，前药或前药的盐，其中A1，A2，A3，A4，R7，R8，R9，X，Y，Z，L，n和m如本文所定义，并且对通过抑制VR1受体预防或改善的疾病有用。
• Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists
  作者：Robert G. Schmidt、Erol K. Bayburt、Steven P. Latshaw、John R. Koenig、Jerome F. Daanen、Heath A. McDonald、Bruce R. Bianchi、Chengmin Zhong、Shailen Joshi、Prisca Honore、Kennan C. Marsh、Chih-Hung Lee、Connie R. Faltynek、Arthur Gomtsyan

  DOI：10.1016/j.bmcl.2011.01.056

  日期：2011.3

  Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition. (C) 2011 Elsevier Ltd. All rights reserved.